5 completed, 2 withdrawn, 1 terminated, 1 unknown. 4 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 1, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 1 | Completed 1 |
Follow Carcinoma of the Head and Neck: new trials by email Literature Review of Carcinoma of the Head and Neck trials Research Report on Carcinoma of the Head and Neck
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs Stage III Breast Cancer, Stage IV Breast Cancer | Withdrawn | Travera Inc | 2024-11-01 | 2024-11-25 | ||
| Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx) Pleural Effusion, Malignant, Ascites, Malignant | Completed | Travera Inc | 72 | 2022-07-15 | 2026-04-13 | |
| Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer Panitumumab-IRDye800, 89-Zirconium (Zr-89) Panitumumab, Pinpoint IR IR9000 fluorescence imaging system (FIS) - Squamous Cell Carcinoma of the Head and Neck, Carcinoma of the Head and Neck | Phase 1 | Completed | Andrei Iagaru | 14 | 2019-01-07 | 2023-05-19 |
| Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137) Talimogene Laherparepvec, Pembrolizumab - Carcinoma of the Head and Neck | Phase 1 | Completed | Amgen | 36 | 2016-04-06 | 2021-09-08 |
| Accelerated Modulated Fractionation (SIB-IMRT) for Head and Neck District Cetuximab plus Radiotherapy - Carcinoma of the Head and Neck | Phase 2 | Unknown | European Institute of Oncology | 10 | 2014-01-01 | 2023-06-28 |
| Study of Cetuximab With Concomitant-boost Radiotherapy in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) Cetuximab - Carcinoma of the Head and Neck | Phase 2 | Completed | Merck KGaA, Darmstadt, Germany | 27 | 2009-03-01 | 2014-03-12 |
| Intensity-Modulated Radiotherapy for Recurrent Head and Neck Cancer IMRT - Carcinoma of the Head and Neck | Phase 2 | Withdrawn | Nilam Ramsinghani | 2004-10-14 | 2017-07-31 | |
| Combination of Taxotere and Oxaliplatin in Squamous Cell Carcinoma of the Head and Neck Taxotere, Oxaliplatin - Carcinoma of the Head and Neck | Phase 2 | Terminated | University of Southern California | 12 | 2004-09-01 | 2014-05-22 |
| Phase II Trial of Allovectin-7® for Head and Neck Cancer Allovectin-7® - Head and Neck Cancer, Squamous Cell Carcinoma of the Oral Cavity or Oropharynx | Phase 3 | Completed | Vical | 2008-06-24 |
Carcinoma (3) · Squamous Cell Carcinoma of Head and Neck (3) · Anus Neoplasms (2) · Appendiceal Neoplasms (2) · Breast Neoplasms (2) · Carcinoma, Hepatocellular (2) · Carcinoma, Neuroendocrine (2) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Renal Cell (2) · Cholangiocarcinoma (2) · Esophageal Neoplasms (2) · Head and Neck Neoplasms (2) · Laryngeal Neoplasms (2) · Lip Neoplasms (2) · Lung Neoplasms (2)
Neoplasms by Histologic Type (5) · Neoplasms by Site (5) · Neoplasms, Glandular and Epithelial (5) · Neoplasms (4) · Carcinoma, Squamous Cell (3) · Head and Neck Neoplasms (3) · Mouth Diseases (3) · Otorhinolaryngologic Diseases (3) · Respiratory Tract Diseases (3) · Stomatognathic Diseases (3) · Adenocarcinoma (2) · Adenoma (2) · Adnexal Diseases (2) · Anus Diseases (2) · Breast Diseases (2)
Cetuximab (2) · Allovectin-7 (1) · Docetaxel (1) · Oxaliplatin (1) · Panitumumab (1) · Radiotherapy (1) · Radiotherapy, Intensity-Modulated (1) · pembrolizumab (1) · talimogene laherparepvec (1)
Travera Inc (2) · Amgen (1) · Andrei Iagaru (1) · European Institute of Oncology (1) · Merck KGaA, Darmstadt, Germany (1) · Nilam Ramsinghani (1) · University of Southern California (1) · Vical (1)
United States (5) · Italy (2) · Australia (1) · Austria (1) · Belgium (1) · Canada (1) · France (1) · Greece (1) · Japan (1) · Spain (1) · Switzerland (1) · United Kingdom (1)
Andrei Iagaru, MD (1) · Barbara Gitlitz, MD (1) · Mark Stevens, Ph.D. (1) · Mark Stevens, Phd (1) · Masataka Ota, MD (1) · Nilam Ramshinghani, MD (1) · Rob Kimmerling, Phd (1) · Robert Kimmerling, Ph.D. (1) · Roberto Orecchia, Prof (1)
2015 (1), P30CA124435 (1), R01CA190306 (1)